Angiotensin-receptor neprilysin inhibitor LCZ696; A novel therapy for heart failure

[No abstract available]

Authors
Mohammad B.I.1 , Hadi N.R.2 , Singh R.B. 3 , Shastun S. 4 , Sharmanov T.5 , Tazhibayev S.5 , Gumarova L.6
Journal
World Heart Journal
Number of issue
1
Language
English
Pages
13-16
Status
Published
Link
External link
Volume
7
Year
2015
Organizations
  • 1 College of Pharmacy, University of Al Qadisiyah, Iraq
  • 2 Department of Pharmacology, Kufa University, Najaf, Iraq
  • 3 Halberg Hospital and Research Institute, Moradabad, India
  • 4 People’s Friendship University of Russia, Moscow, Russian Federation
  • 5 Kazakh Academy of Nutrition, Almaty, Kazakhstan
  • 6 Al-Farabi Kazakh National University, Almaty, Kazakhstan
Keywords
angiotensin receptor; carnitine; enalapril; eplerenone; hydralazine plus isosorbide dinitrate; membrane metalloendopeptidase; omega 3 fatty acid; sacubitril plus valsartan; ubidecarenone; valsartan; Article; atrial fibrillation; cardiovascular mortality; cardiovascular risk; clinical feature; diabetes mellitus; drug efficacy; drug mechanism; food and drug administration; heart ejection fraction; heart failure; heart left ventricle ejection fraction; heart left ventricle wall; heart volume; hospitalization; human; kidney function; morbidity; New York Heart Association class; nutritional deficiency; phase 2 clinical trial (topic); randomized controlled trial (topic); renin angiotensin aldosterone system; systolic blood pressure
Date of creation
19.10.2018
Date of change
19.10.2018
Short link
https://repository.rudn.ru/en/records/article/record/4800/
Share

Other records